When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Leucemia de células pilosas

Última revisão: 13 Feb 2025
Última atualização: 25 Oct 2024

Resumo

Definition

History and exam

Key diagnostic factors

  • presença de fatores de risco
  • desconforto ou plenitude abdominal
  • esplenomegalia
Full details

Other diagnostic factors

  • fraqueza e fadiga
  • perda de peso inexplicada
  • hematomas e sangramento
  • palidez
  • infecções recorrentes
  • hepatomegalia
  • linfadenopatia
  • achados neurológicos
  • distúrbios imunológicos sistêmicos associados
Full details

Risk factors

  • meia-idade
  • sexo masculino
  • ascendência branca
  • localização no hemisfério ocidental
  • exposições ambientais
  • predisposição genética
  • Vírus Epstein-Barr
  • mononucleose infecciosa
Full details

Diagnostic tests

1st tests to order

  • Hemograma completo com diferencial
  • esfregaço de sangue periférico
  • biópsia e aspiração da medula óssea por trefina (avaliação morfológica)
  • imunofenotipagem (imuno-histoquímica ou citometria de fluxo)
  • perfil metabólico completo
  • lactato desidrogenase (LDH) sérica
  • sorologia viral para hepatite B e C
Full details

Tests to consider

  • análise molecular (para mutação BRAF V600E ou rearranjo IGHV4-34)
  • TC de tórax, abdome e pelve
Full details

Treatment algorithm

ACUTE

nenhuma indicação(ões) para tratamento

indicação(ões) para tratamento presente(s): ausência de ruptura esplênica ou esplenomegalia maciça ou trombocitopenia acentuada que impeça a quimioterapia

indicação(ões) para tratamento presente(s): com esplenomegalia sintomática maciça ou ruptura esplênica ou trombocitopenia acentuada que impeça a quimioterapia

ONGOING

recidiva precoce (<2 anos) ou doença refratária

recidiva tardia (≥2 anos)

Contributors

Authors

Ambuj Kumar, MD, MPH

Professor

USF Health Office of Research

Department of Internal Medicine, College of Medicine

Moffitt Cancer Center & Research Institute, Department of Health Outcomes & Behavior

University of South Florida

Tampa

FL

Disclosures

AK declares that he has no competing interests.

Mohamed A. Kharfan-Dabaja, MD, MBA, FACP

Professor

Division of Hematology-Oncology

Blood and Marrow Transplantation Program

Mayo Clinic

Jacksonville

FL

Disclosures

MKD declares that he has no competing interests.

Acknowledgements

Dr Ambuj Kumar and Dr Mohamed Kharfan-Dabaja would like to gratefully acknowledge Dr Benjamin Djulbegovic, a previous contributor to this topic.

Disclosures

BD declares that he has no competing interests.

Peer reviewers

Daniel Catovsky, MD, FRCP, FRCPath, DSc, FMedSc

Consultant Haemato-Oncologist

Section of Haemato-Oncology

Brookes Lawley Institute of Cancer

Sutton

UK

Disclosures

DC declares that he has no competing interests.

Roger Lyons, MD

Clinical Professor of Medicine

University of Texas Health Science Center San Antonio

San Antonio

TX

Disclosures

RL declares that he has no competing interests.

Rebecca Connor, MD

Chief Fellow

Section of Hematology and Oncology

Department of Internal Medicine

Wake Forest University Baptist Medical Center

Winston-Salem

NC

Disclosures

RC declares that she has no competing interests.

Claire Dearden, BSc, MD, FRCP, FRCPath

Consultant Haematologist

The Royal Marsden Hospital

Sutton

Surrey

UK

Disclosures

CD declares that she has no competing interests.

  • Leucemia de células pilosas images
  • 鉴别诊断

    • Leucemia linfocítica crônica (LLC)
    • Linfoma de células do manto
    • Leucemia pró-linfocítica
    More Differentials
  • 指南

    • NCCN clinical practice guidelines in oncology: hairy cell leukemia
    • Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL-V)
    More 指南
  • padlock-locked登录或订阅即可浏览 BMJ Best Practice 临床实践完整内容

内容使用需遵循免责声明